Tango Therapeutics, Inc.
About Tango Therapeutics, Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $62.4M
- Net income
- -$101.6M
- Total assets
- $398.7M
- Market cap
- $2.9B
- Operating margin
- -178.4%
- Net margin
- -162.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $62.4M
- Operating expenses
- $173.7M
- Operating income
- -$111.3M
- Income tax
- $4.0K
- Net income
- -$101.6M
- EPS (basic)
- $-0.87
- EPS (diluted)
- $-0.87
Balance sheet
- Total assets
- $398.7M
- Current assets
- $353.8M
- Total liabilities
- $52.5M
- Current liabilities
- $21.7M
- Shareholders’ equity
- $346.2M
Cash flow
- Operating cash flow
- -$138.9M
- Investing cash flow
- -$40.9M
- Financing cash flow
- $222.5M
- Net cash flow
- $42.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.9B
- EPS (diluted)
- $-0.87
- Shares outstanding
- 94.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 11, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $101.6M in FY2025.
- Revenue grew 68% from FY2021 to FY2025.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tango Therapeutics, Inc..
Write a review
News about Tango Therapeutics, Inc.
News & sentiment via Polygon.io
